2-Adamantanol is a bicyclic alcohol derived from adamantane. It's a white crystalline solid with a characteristic camphor-like odor. 2-adamantanol has been studied for its potential applications in various fields. Its synthesis often involves the oxidation of adamantane or the reduction of 2-adamantanone. It is known to exhibit biological activity, including anti-inflammatory and analgesic effects. 2-adamantanol is also used as a building block in the synthesis of other complex molecules, including pharmaceuticals and materials. The study of 2-adamantanol has been driven by its unique structural features, biological activity, and potential for further development.'
| ID Source | ID |
|---|---|
| PubMed CID | 64149 |
| CHEMBL ID | 1269176 |
| SCHEMBL ID | 350390 |
| SCHEMBL ID | 13082659 |
| MeSH ID | M0226880 |
| Synonym |
|---|
| HMS1787B03 |
| tricyclo[3.3.1.13,7]decan-2-ol |
| 2-hydroxyadamantane |
| nsc193480 |
| 700-57-2 |
| nsc-193480 |
| 2-adamantanol , |
| adamantan-2-ol |
| inchi=1/c10h16o/c11-10-8-2-6-1-7(4-8)5-9(10)3-6/h6-11h,1-5h |
| STK365644 |
| tricyclo[3.3.1.1~3,7~]decan-2-ol |
| 2-adamantanol, 97% |
| A0720 |
| AKOS001023938 |
| A836750 |
| bdbm50329319 |
| CHEMBL1269176 , |
| einecs 211-846-7 |
| tricyclo(3.3.1.13,7)decan-2-ol |
| nsc 193480 |
| FT-0610989 |
| SCHEMBL350390 |
| DTXSID00220266 |
| 2-tricyclo[3.3.1.13,7]decanol |
| 2-tricyclo[3.3.1.13, 7]decanol |
| tricyclo[3.3.1.1(3,7)]decan-2-ol |
| tricyclo[3.3.1.1<3,7>]decan-2-ol |
| W-104572 |
| SCHEMBL13082659 |
| mfcd00074744 |
| CS-W000383 |
| AC-8481 |
| Z56757309 |
| F15454 |
| AKOS034830296 |
| EN300-16725 |
| HY-W000383 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Optimization for increased adipocyte potency, metabolic stability and selectivity afforded 11k and 11l, both of which were >25% orally bioavailable in rat." | ( Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1. Berbaum, J; Bruno, JG; Bukhtiyarov, Y; Claremon, DA; Gregg, RE; Guo, J; Guo, R; Harrison, RK; Howard, L; Johnson, JA; Krosky, PM; Kruk, BA; Leftheris, K; Lindblom, PR; McGeehan, GM; McKeever, BM; Nar, H; Panemangalore, R; Schuler-Metz, A; Scott, BB; Singh, SB; Tice, CM; Togias, J; Ye, YJ; Zhao, W; Zhao, Y; Zhuang, L, 2010) | 0.36 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 1.7536 | 10.0000 | AID527526 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0000 | 2.0151 | 10.0000 | AID527528 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 (µMol) | 22.0000 | 0.0000 | 2.8005 | 10.0000 | AID527527 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytoplasm | Cytochrome P450 3A4 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Cytochrome P450 3A4 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 3A4 | Homo sapiens (human) |
| mitochondrion | Cytochrome P450 2D6 | Homo sapiens (human) |
| endoplasmic reticulum | Cytochrome P450 2D6 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Cytochrome P450 2D6 | Homo sapiens (human) |
| cytoplasm | Cytochrome P450 2D6 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 2D6 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Cytochrome P450 2C9 | Homo sapiens (human) |
| plasma membrane | Cytochrome P450 2C9 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 2C9 | Homo sapiens (human) |
| cytoplasm | Cytochrome P450 2C9 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 2C9 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID527513 | Metabolic stability in rat liver microsomes assessed as half life | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1. |
| AID527526 | Inhibition of CYP3A4 | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1. |
| AID527528 | Inhibition of CYP2D6 | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1. |
| AID527527 | Inhibition of CYP2C9 | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.24) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||